Zacks Investment Research downgraded shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) from a buy rating to a hold rating in a report issued on Friday morning.
According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “
A number of other equities analysts also recently commented on GLMD. Maxim Group reaffirmed a buy rating and set a $9.00 target price (down from $24.00) on shares of Galmed Pharmaceuticals in a research note on Monday, August 1st. FBR & Co set a $20.00 target price on shares of Galmed Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 5th. Finally, HC Wainwright reaffirmed a buy rating on shares of Galmed Pharmaceuticals in a research note on Monday, November 7th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of Buy and an average price target of $12.20.
Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) opened at 3.7499 on Friday. Galmed Pharmaceuticals has a 12 month low of $2.78 and a 12 month high of $9.70. The stock has a 50 day moving average of $3.69 and a 200 day moving average of $4.20. The stock’s market cap is $45.56 million.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.05. On average, equities analysts anticipate that Galmed Pharmaceuticals will post ($1.39) earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. P.A.W. Capital Corp purchased a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $266,000. P.A.W. Capital Corp owned about 0.54% of Galmed Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 5.82% of the company’s stock.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.